ES2682981T3 - Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas - Google Patents

Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas Download PDF

Info

Publication number
ES2682981T3
ES2682981T3 ES14799913T ES14799913T ES2682981T3 ES 2682981 T3 ES2682981 T3 ES 2682981T3 ES 14799913 T ES14799913 T ES 14799913T ES 14799913 T ES14799913 T ES 14799913T ES 2682981 T3 ES2682981 T3 ES 2682981T3
Authority
ES
Spain
Prior art keywords
amino acid
hemagglutinin
virus proteins
flu virus
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14799913T
Other languages
English (en)
Inventor
Christopher Patrick Marshall
Peter Joseph Alff
Claudio BERTUCCIOLI
Mark Andrew Yondola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avatar Medical LLC
Original Assignee
Avatar Medical LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avatar Medical LLC filed Critical Avatar Medical LLC
Application granted granted Critical
Publication of ES2682981T3 publication Critical patent/ES2682981T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)

Abstract

Un polipéptido, proteína o complejo de proteínas de hemaglutinina (HA) del virus de la gripe, que comprende un dominio de tallo de la HA que comprende una secuencia de aminoácidos que tiene una identidad de secuencia de al menos 65% con los restos de aminoácidos 229 a 519 de la SEQ ID NO: 1, en donde la secuencia de aminoácidos comprende una mutación puntual a tirosina en una o más de las posiciones de aminoácidos 403, 406, 429, 432, 433 y 435, o un resto de aminoácido que corresponde a las mismas por alineamiento con la SEQ ID NO: 1.
ES14799913T 2013-08-03 2014-08-02 Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas Active ES2682981T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361861989P 2013-08-03 2013-08-03
PCT/US2014/049509 WO2015020913A2 (en) 2013-08-03 2014-08-02 Influenza hemagglutinin proteins and methods of thereof

Publications (1)

Publication Number Publication Date
ES2682981T3 true ES2682981T3 (es) 2018-09-24

Family

ID=51905385

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14799913T Active ES2682981T3 (es) 2013-08-03 2014-08-02 Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
ES18156060T Active ES2832733T3 (es) 2013-08-03 2014-08-02 Métodos de preparación y uso de complejos de hemaglutinina del virus de la gripe

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18156060T Active ES2832733T3 (es) 2013-08-03 2014-08-02 Métodos de preparación y uso de complejos de hemaglutinina del virus de la gripe

Country Status (6)

Country Link
US (4) US9393297B2 (es)
EP (3) EP3395826B1 (es)
JP (2) JP6704849B2 (es)
CA (1) CA2920016A1 (es)
ES (2) ES2682981T3 (es)
WO (1) WO2015020913A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3024483B1 (en) 2013-07-25 2020-01-15 Calder Biosciences Inc. Conformationally stabilized rsv pre-fusion f proteins
EP3395826B1 (en) * 2013-08-03 2020-10-14 Calder Biosciences Inc. Methods of making and using influenza virus hemagglutinin complexes
CA3000313A1 (en) * 2015-10-08 2017-04-13 The Governors Of The University Of Alberta Hepatitis c virus e1/e2 heterodimers and methods of producing same
CA3012703A1 (en) 2016-02-03 2017-08-10 Cg Discovery, Inc. Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites
US11596683B2 (en) * 2016-07-12 2023-03-07 Duke University Engineered influenza polynucleotides, viruses, vaccines and methods of making and using the same
WO2018213097A1 (en) * 2017-05-15 2018-11-22 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
JP2020532953A (ja) 2017-08-07 2020-11-19 カルダー・バイオサイエンシズ・インコーポレイテッド コンフォメーションが安定化されたｒｓｖ融合前ｆタンパク質
JP7317047B2 (ja) * 2018-01-23 2023-07-28 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
US11623004B2 (en) 2018-03-16 2023-04-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncytial virus infection
US20210395333A1 (en) * 2018-06-07 2021-12-23 Palleon Pharmaceuticals Inc. Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder
US11642407B2 (en) * 2020-02-28 2023-05-09 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
US20230310575A1 (en) * 2020-09-02 2023-10-05 St. Jude Children's Research Hospital, Inc. Hemagglutinin Modifications for Improved Influenza Vaccine Production
CN114703207B (zh) * 2022-04-07 2023-05-23 华南农业大学 重组质粒的制备方法和重组病毒

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
ES2367475T3 (es) * 1999-10-15 2011-11-03 Avatar Medical, L.L.C. Proteínas estabilizadas.
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
JP5009614B2 (ja) 2003-07-03 2012-08-22 アバター バイオテクノロジーズ，インク． 免疫原性を低減した分子の取得方法
US20070042001A1 (en) * 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
EP3524619A1 (en) * 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
WO2011066221A1 (en) 2009-11-24 2011-06-03 International Aids Vaccine Initiative Immunogen prioritization for vaccine design
WO2011146120A2 (en) 2010-05-18 2011-11-24 Marshall Christopher P Assay for identifying antigens that activate b cell receptors comprising neutralizing antibodies
US20130289246A1 (en) 2010-09-30 2013-10-31 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
SG11201402633UA (en) * 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
US20130302366A1 (en) 2012-05-09 2013-11-14 Christopher Marshall Conformationally Specific Viral Immunogens
EP3024483B1 (en) 2013-07-25 2020-01-15 Calder Biosciences Inc. Conformationally stabilized rsv pre-fusion f proteins
EP3395826B1 (en) * 2013-08-03 2020-10-14 Calder Biosciences Inc. Methods of making and using influenza virus hemagglutinin complexes

Also Published As

Publication number Publication date
EP3395826B1 (en) 2020-10-14
JP2016530881A (ja) 2016-10-06
JP7298046B2 (ja) 2023-06-27
ES2832733T3 (es) 2021-06-11
US20220288189A1 (en) 2022-09-15
WO2015020913A3 (en) 2015-04-09
EP3805254A1 (en) 2021-04-14
EP3027640A2 (en) 2016-06-08
WO2015020913A2 (en) 2015-02-12
EP3395826A1 (en) 2018-10-31
US20180243403A1 (en) 2018-08-30
US9393297B2 (en) 2016-07-19
US20150056233A1 (en) 2015-02-26
JP2020156487A (ja) 2020-10-01
EP3027640B1 (en) 2018-03-07
US11129887B2 (en) 2021-09-28
CA2920016A1 (en) 2015-02-12
JP6704849B2 (ja) 2020-06-03
US20170072045A1 (en) 2017-03-16

Similar Documents

Publication Publication Date Title
ES2682981T3 (es) Proteínas de hemaglutinina del virus de la gripe y método de uso de las mismas
CL2018003148A1 (es) Proteínas de fusión y usos de las mismas.
CL2018000232A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
PE20170291A1 (es) Vacunas contra virus de influenza y usos de las mismas
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
CO2017006580A2 (es) Anticuerpos humanos para hemaglutinina de influenza
PE20170290A1 (es) Vacunas contra virus de influenza y usos de las mismas
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
PH12015502612B1 (en) Influenza virus vaccines and uses thereof
PE20210651A1 (es) Vacunas contra virus de la gripe y usos de las mismas
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
CL2017003228A1 (es) Fragmentos mutantes de proteína ras
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
CO2018000171A2 (es) Metodos de purificacion y/o inactividad viral
PE20180162A1 (es) Polipeptidos dirigidos a la fusion de vih
WO2014152946A3 (en) Polypeptides for treating and/or limiting influenza infection
EA201400235A1 (ru) Вакцины против гриппа на основе н5
MA42312A (fr) Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine
MX2019007924A (es) Vacunas contra la influenza.
AR094846A1 (es) Proteínas h5 del virus de la gripe h5n1 para uso como un medicamento
EA201892385A1 (ru) Модификация сконструированных полипептидов гемагглютинина вируса гриппа